VANCOUVER, BC, May 11, 2022 /PRNewswire/ – Atmofizer Technologies Inc. (the “Company” or “atmovisor“) (CSE: ATMO) (Frankfurt: J3K) (OTCQB: ATMFF) is pleased to announce the company’s test results of its airborne nanoparticle agglomeration engine. Recent test results at Atmofizer Toronto showed that the Company’s technology, before the use of an air filter, reduced the number of airborne ultrafine particles below one micron by 81.7%, while doubling the larger particles at 2.5 microns. The company says this is scientifically and medically significant, as it shows the elimination of the smallest airborne nanoscopic particles (including toxic industrial pollution, smoke and infectious disease). These particles are small enough that they can enter the bloodstream and directly enter the brain and vital organs by being inhaled into the lungs. Particles smaller than 2.5 microns are generally considered the measure of air quality because they pose a risk to humans and animals. Doubling the amount of particles above 2.5 microns shows that smaller particles are indeed clumped together into larger clusters using the Company’s technology. These larger clusters are usually more easily filtered out by body and common air filters. It is also significant that these results are obtained without the use of a filter.
The Company has also added additional staff to its Toronto testing facility to focus on the application of its agglomeration technology in mobile aftermarket (transportation vehicles) and HVAC applications. The additional staff will allow the company to more quickly test and evaluate new Atmofizer airflow configurations and prototypes.
“The test results we’ve seen so far are very encouraging,” said White pepper, president and chief commercial officer of Atmofizer. “We believe we will continue to close the filter gap by making it easier to capture and neutralize the most elusive particles. 0.3 microns is considered the most penetrating particle size – the most difficult particle size to manage for an air filter, even HEPA. These tests have shown that an Atmofizer can reduce smaller particles and then triple the number of particles above 0.3. This pushes significantly more particles out of the size range the most dangerous and difficult step towards a more manageable size for air filters and ultraviolet lamps to manage more efficiently and effectively to improve air quality.And all of this was done without using an air filter Independent third-party lab tests have also shown that particles clumped together by even our small, portable Atmofizer cause those particles to be more effectively neutralized by UV light. Also showed that our second-generation A500 Agglomeration Engine neutralized a 99.99% COVID-19 surrogate, also without using a filter. reinforces our position that Atmofizer’s technology can improve the performance of other devices and systems that our customers may already have in their air purification systems.”
About Atmofizer Technologies Inc.
Atmofizer’s consumer and industrial solutions are based on its patented and patent-pending technology for the agglomeration and neutralization of ultrafine particles. This capability creates a revolutionary and more efficient method of dealing with the wide range of dangerous nanoparticles, viruses and bacteria that are too small to be effectively handled by conventional HEPA filters and ultraviolet lamps. Atmofizer plans to disrupt the air treatment industry by improving air safety and purification efficiency while reducing operating costs for customers.
Atmofiizing the air refers to the process of using ultrasonic sound waves to agglomerate (cluster) small particles into a larger target which is then irradiated with ultraviolet light to neutralize their harmful properties, making the air you breathe less dangerous to your health. Using units that atmofize the air in tandem with HEPA filters can make HEPA filters more efficient, allow the use of a less powerful filter, and result in a cleaner, longer lasting filter that reduces operating costs. operation and poses fewer health risks. clean or replace.
Atmofizer is the only source of patent-pending, patent-protected technology to atmofize air and applies its proprietary technology in consumer and industrial air purification products currently manufactured under the Atmofizer brand, as well as in retail and commercial devices produced by other companies that incorporate Atmofizer technology into their own licensed products. Atmofizer’s owned and licensed product lines include portable, portable and mobile use for personal air handling, as well as larger systems to handle higher air volumes for commercial, industrial, institutional and residential.
This press release contains “forward-looking information” within the meaning of applicable securities laws. Any statements contained herein that are not clearly historical in nature may constitute forward-looking information. In some instances, forward-looking information may be identified by words or phrases such as “may”, “will”, “expect”, “probable”, “should”, “would”, “expect”, ” anticipates”, “intend”, “potential”, “proposed”, “estimate”, “believe” or the negative form of these terms, or other similar words, phrases and grammatical variations, or statements that certain events or conditions “can” or “will” happen, or through discussions of strategy. Forward-looking information contained herein includes, but is not limited to, Atmofizer’s technology and its future uses, and the Company’s business and strategic plans.
By its nature, forward-looking information is subject to inherent risks and uncertainties which may be general or specific and which give rise to the possibility that the expectations, forecasts, predictions, projections or conclusions will not prove to be accurate, that the assumptions are not correct and that the objectives, strategic goals and priorities will not be achieved. A variety of factors, including known and unknown risks, many of which are beyond our control, could cause actual results to differ materially from the forward-looking information contained in this press release, including, without limitation: the ability to the Company to comply with all applicable laws and governmental regulations relating to its commercial products; the Company’s ability to protect its intellectual property; impacts on the Company’s business and operations due to the COVID-19 pandemic; the conflict in the east Europe; having only a limited operating history, the Company’s ability to access capital to meet its future financing needs; the Company’s dependence on management and key personnel; competition; changes in consumer trends; foreign currency fluctuations; and general economic, market or business conditions.
Other risk factors can also be found in the Company’s continuous disclosure documents, which have been filed on SEDAR and can be viewed at www.sedar.com. Readers are cautioned to carefully consider these factors, as well as other factors, uncertainties and potential events, and not to place undue reliance on any forward-looking information. The forward-looking information contained herein is made as of the date of this press release and is based on the beliefs, estimates, expectations and opinions of management as of the date such forward-looking information is made. The Company undertakes no obligation to update or revise any forward-looking information, whether as a result of new information, estimates or opinions, future events or results or otherwise, or to explain any material differences between subsequent actual events and such forward-looking information, except as required by applicable law.
SOURCEAtmofizer Technologies Inc.